

# Application News

## No. B91

### MALDI-TOF Mass Spectrometry

## Typing of *emm1* Group A Streptococci Using MALDI-TOF MS and the Statistical Analysis Software eMSTAT Solution™

Microbial identification techniques using matrix-assisted laser desorption/ionization mass spectrometers (MALDI-TOF MS) are becoming more common as the process of identification is faster and simpler than conventional methods. MALDI-TOF MS has already gained a position as an instrument for identification techniques. For further expansion, numerous efforts are being made to utilize MALDI instruments for microbial tests other than identification.

Recently, invasive infections caused by group A streptococcus (GAS) are on the increase. Among these, the *emm1* group A streptococci has high pathogenicity, and its invasive infection cases indicate a significantly high possibility of developing into a fulminant form. It is said that both its case fatality rate and rate of complications are high. This article introduces an example of differentiating between the highly pathogenic *emm1* type and other types using MALDI-TOF MS and the statistical analysis software eMSTAT Solution.

K. Shima

### Materials and Methods

First, among the GAS strains derived from invasive infections, we used 10 strains each of *emm1*, *emm12*, *emm28* and *emm89*, which have a high isolation frequency, and conducted a search for markers that help to differentiate *emm* types.

The above four *emm* types were cultured on a blood agar medium for 24 hours, subjected to ethanol-formic acid extraction, and analyzed on the iD<sup>plus</sup> MALDI microbial identification platform using sinapinic acid as a matrix. To ensure the repeatability of markers, samples were prepared from the re-cultured colonies and each type was measured nine times in total. The peak lists obtained from the mass spectra were subjected to multivariate analysis using the eMSTAT Solution software to differentiate *emm* types. Furthermore, we conducted blind tests using 379 strains derived from pharyngitis and tonsillitis, including groups B, C, and G streptococci.

### Results

Fig. 1 shows mass spectra of the group A streptococcus *emm1* type and other types. The mass spectrum patterns were similar and it was a challenge to differentiate them visually. However, by performing multivariate analysis (algorithm: PLS-DA), they were classified into two groups: the *emm1* type and the other types (Fig. 2).




Fig. 2 Results of Multivariate Analysis of Group A Streptococcus (Score Plot)




Fig. 1 Comparison of Mass Spectra of the Group A Streptococcus *emm1* Type and the Other Types

Using the eMSTAT Solution software, it was possible to distinguish marker peaks detected in the MALDI spectra which help to differentiate the *emm1* type from the other types. As a result of the search, we confirmed from the Peak Matrix table that the peak at *m/z* 10932 was detected with all 90 samples of the *emm1* type and, in contrast to this, was not detected with all samples of the other types (Fig. 3). This was confirmed in the mass spectra where we can see that the peak at *m/z* 10932 was detected only with the *emm1* type (Fig. 4).

Next, we conducted a blind test of 379 clinically isolated strains using a marker peak of *m/z* 10932 as an indicator (Table 1). Among 379 strains, 97 strains were typed as the *emm1* type using a conventional genetic analysis, while 92 strains among these 97 strains (94.8 %) were typed as the *emm1* type using the MALDI-TOF MS technique, which indicates a high positive agreement rate. In addition, 3 strains typed as non *emm1* type using the MALDI-TOF MS method were typed as *emm11* (n=1) and *emm28* (n=2) by the conventional method, which indicates a negative agreement rate of 98.9 % (Table 2).

Peak Matrix							
1519 peaks							
<input type="checkbox"/>	<i>m/z</i>	ANOVA	<i>emm1.0</i>	<i>emm12.0</i>	<i>emm28.0</i>	<i>emm89.0</i>	
<input checked="" type="checkbox"/>	10529.53	0.45215	0	1	0	0	
<input checked="" type="checkbox"/>	10580.12	0.022573	0	0	0	4	
<input checked="" type="checkbox"/>	10689.77	0.13804	5	1	9	2	
<input checked="" type="checkbox"/>	10697.97	1.1797E-16	64	80	55	84	
<input checked="" type="checkbox"/>	10706.51	0.32824	3	2	0	0	
<input checked="" type="checkbox"/>	10717.11	0.76438	2	1	2	3	
<input checked="" type="checkbox"/>	10725.56	0.27327	0	0	1	2	
<input checked="" type="checkbox"/>	10734.97	0.26564	0	2	0	4	
<input checked="" type="checkbox"/>	10918.12	4.173E-74	0	88	90	89	
<input checked="" type="checkbox"/>	10931.66	8.8298E-56	90	0	0	0	
<input checked="" type="checkbox"/>	10951.27	0.45215	0	1	0	0	
<input checked="" type="checkbox"/>	10963.42	0.0097304	0	0	0	7	
<input checked="" type="checkbox"/>	10970.66	0.45215	1	0	0	0	
<input checked="" type="checkbox"/>	11000.27	0.0046591	6	0	0	0	
<input checked="" type="checkbox"/>	11007.57	0.45215	1	0	0	0	
<input checked="" type="checkbox"/>	11025.18	0.13935	0	3	0	0	

Fig. 3 Identification of Marker Peaks using the Peak Matrix Function




Fig. 4 Enlarged Mass Spectra of the Group A Streptococcus *emm1* Type and the Other Types

<References>

Sakuma M, Morozumi M, Ubukata K, Iwata T, 2018. Discrimination of group A streptococcus *emm1* type using MALDI-TOF MS. Joint Meeting of the 67th Regional Meeting of the Japanese Association for Infectious Diseases (JAID) and the 65th Annual Meeting of Japanese Society of Chemotherapy (JSC) in the East Japan District

<Acknowledgments>

This article has been created on the basis of the results obtained in the collaborative research with the Department of Infectious Diseases Keio University School of Medicine.

eMSTAT Solution is a trademark of Shimadzu Corporation in Japan and/or other countries.

This product can be used for research purposes only. This has not been approved or certified as a medical device under the Pharmaceutical and Medical Device Act of Japan.

It cannot be used for the purpose of medical examination and treatment or related procedures.

■ Conclusion

Conventionally, the *emm* typing techniques need culturing, GAS isolation, *emm* gene amplification by PCR, and sequence analysis, and it takes three days before the result is obtained. On the other hand, using MALDI-TOF MS, the result can be obtained within several tens of minutes after culturing. This is a new technique for typing the highly pathogenic *emm1* type in a short time, and its future development can be expected.

Table 1 Clinically Isolated Strains Used for Blind Test

<i>emm1</i>	97
<i>emm2</i>	2
<i>emm3</i>	4
<i>emm4</i>	31
<i>emm6</i>	2
<i>emm9</i>	7
<i>emm11</i>	11
<i>emm12</i>	92
<i>emm28</i>	59
<i>emm75</i>	6
<i>emm77</i>	1
<i>emm89</i>	58
<i>emm112</i>	3
Other	6
<b>Total</b>	<b>379</b>

Table 2 Results of Blind Test

<i>emm1</i> Type	Conventional Method (Genetic Analysis)		Total
	(+)	(-)	
Mass Spectrometry (+)	92 (94.8 %)	3 (1.1 %)	95
Mass Spectrometry (-)	5 (5.2 %)	279 (98.9 %)	284
<b>Total</b>	<b>97</b>	<b>282</b>	<b>379</b>



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.